Thermo Fisher Scientific
The 10-second takeaway
For the quarter ended Sep. 29 (Q3), Thermo Fisher Scientific beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded significantly.
Gross margins grew, operating margins contracted, net margins grew.
Thermo Fisher Scientific reported revenue of $3.09 billion. The 16 analysts polled by S&P Capital IQ predicted revenue of $2.99 billion on the same basis. GAAP reported sales were 3.8% higher than the prior-year quarter's $2.97 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.19. The 20 earnings estimates compiled by S&P Capital IQ predicted $1.16 per share. GAAP EPS of $0.80 for Q3 were 16% higher than the prior-year quarter's $0.69 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.9%, 190 basis points better than the prior-year quarter. Operating margin was 11.9%, 50 basis points worse than the prior-year quarter. Net margin was 9.4%, 50 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $3.12 billion. On the bottom line, the average EPS estimate is $1.27.
Next year's average estimate for revenue is $12.28 billion. The average EPS estimate is $4.82.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 551 members out of 572 rating the stock outperform, and 21 members rating it underperform. Among 160 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 157 give Thermo Fisher Scientific a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermo Fisher Scientific is outperform, with an average price target of $63.97.
- Add Thermo Fisher Scientific to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.